QVAR TPP — Settlement Summary

Last Modified on 09/22/2026 2:29 pm EDT

QVAR & QVAR Redihaler Inhaler Antitrust Class Action Settlement (TPP)

Summary

This settlement resolves antitrust claims against Teva Pharmaceuticals alleging that Teva unlawfully listed patents in the FDA's Orange Book and engaged in "product hops" to delay generic competition for QVAR and QVAR Redihaler inhalers, causing purchasers and third-party payors to overpay. Teva has agreed to pay **$35 million** into a Settlement Fund and to request removal of certain patents from the Orange Book. The case is pending in the United States District Court for the District of Massachusetts.

Announcements

No special announcements or status alerts are currently posted on the settlement website beyond the standard case timeline. The claim filing deadline is **July 31, 2026**. The Fairness Hearing is scheduled for **August 5, 2026**.

Settlement Amount

Teva will pay **$35,000,000** into a Settlement Fund. The fund will be used to cover:

- Payments to eligible Class Members (Net Settlement Fund)
- Attorneys' fees of up to **33%** of the Settlement Fund
- Unreimbursed litigation costs and expenses of up to **$890,000**
- Reasonable notice and administration costs
- Service awards of **$25,000** to each of the four class representatives

Individual or per-claimant payment amounts are not yet published on the settlement website; amounts will depend on the number of valid claims filed and the Plan of Allocation.

In addition to monetary relief, Teva has agreed to request the **delisting of certain patents from the FDA's Orange Book**, removing barriers to generic QVAR market entry.

Class Period

January 1, 2015 through July 31, 2025

Filing Deadline

July 31, 2026 — Claim Forms must be postmarked (if mailed) or received online by this date.

Who Qualifies

The Class includes all persons or entities that, for consumption by themselves, their families, or their members, insureds, or beneficiaries:

- Purchased, paid for, and/or provided reimbursement for some or all of the purchase price of**QVAR and/or QVAR Redihaler**

- Made such purchases in the **Class States** (see settlement documents for the specific list of states)
- Made such purchases **other than for resale**
- Made such purchases at any time during the Class Period (January 1, 2015 – July 31, 2025)

This class is structured for **third-party payors (TPPs)** such as health and welfare funds, insurers, and similar entities, as well as individual consumers who paid out-of-pocket.

Who Is Excluded

The settlement website does not publish a detailed exclusions list on the home page. Purchasers who bought QVAR or QVAR Redihaler **for resale** are expressly excluded from the Class. Refer to the full Class Notice and Settlement Agreement (available under the Court Documents tab at *www.QVARantitrustsettlement.com*) for the complete list of excluded parties.

How to File

- **Step 1:** Confirm eligibility — verify that your organization or clients purchased, paid for, or reimbursed QVAR or QVAR Redihaler in a Class State between January 1, 2015 and July 31, 2025, other than for resale.
- **Step 2:** Obtain the Claim Form — download or access the form via the *File a Claim* tab on the official settlement website at **www.QVARantitrustsettlement.com**.
- **Step 3:** Complete the Claim Form — provide all required purchase and payment information.
- **Step 4:** Submit the Claim Form by **July 31, 2026** using one of the following methods:
  - **Online:** Submit electronically through the settlement website by July 31, 2026 (received by deadline).
  - **Mail:** Print and mail the completed Claim Form, postmarked no later than July 31, 2026, to:
    QVAR Antitrust Settlement
    c/o A.B. Data, Ltd.
    PO Box 173034
    Milwaukee, WI 53217
- **Step 5:** Retain a copy of the submitted Claim Form and any confirmation for your records.

Important: Class Members who do not file a Claim Form will not receive any payment from the Settlement, even if they do not exclude themselves.

Key Dates & Options

- **Exclusion (Opt-Out) Deadline:** June 15, 2026 — must be postmarked by this date to preserve the right to sue Teva independently.
- **Objection Deadline:** June 15, 2026 — written objections must be postmarked by this date.
- **Claim Filing Deadline:** July 31, 2026.
- **Fairness Hearing:** August 5, 2026, at 2:00 p.m. Eastern — Courtroom 4, John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Boston, Massachusetts 02210. (Date, time, and location subject to change; check settlement website for updates.)

Defendants

- **Teva Pharmaceuticals** — Manufacturer and marketer of QVAR and QVAR Redihaler branded inhalers. Plaintiffs allege Teva:
  - Unlawfully listed certain patents in the FDA's Orange Book for QVAR that did not meet the applicable listing requirements, triggering automatic 30-month delays in generic market entry;
  - Engaged in "product hops" — discontinuing existing QVAR inhaler versions and switching to new versions — to obtain new patent protections and artificially maintain elevated prices;

    - Through these actions, delayed the entry of lower-cost generic QVAR products, causing overcharges to purchasers and payors in violation of state and federal antitrust and consumer protection laws.

Teva denies all allegations and maintains it did nothing wrong. No court or jury has determined that the allegations have been proven.

Case History

- **Case Name:** *Iron Workers District Council of New England Health and Welfare Fund, et al. v. Teva Pharm. et al*
- **Case Number:** 23-cv-11131-NMG
- **Court:** United States District Court for the District of Massachusetts
- **Class Period Conduct:** January 1, 2015 – July 31, 2025
- **Settlement Fund Agreed:** $35,000,000
- **Fairness Hearing Scheduled:** August 5, 2026
- Additional case history milestones (e.g., complaint filing date, class certification, settlement preliminary approval date) are not detailed on the settlement website home page. Refer to Court Documents at *www.QVARantitrustsettlement.com* for full docket information.

Source

www.QVARantitrustsettlement.com (Official Settlement Website, QVAR TPP Home Page)

Last Updated

2026-09-22

Reviewer Flags

- **Draft Status:** First draft — no previous version exists in the knowledge base.
- **Source Pages:** All information in this article was drawn exclusively from the QVAR Antitrust Settlement home page (www.QVARantitrustsettlement.com), as provided. No additional pages (e.g., FAQs, Court Documents, File a Claim) were available for synthesis.
- **Class States Not Specified:** The home page references "Class States" but does not enumerate them. Reviewers should check the full Class Notice or Settlement Agreement on the Court Documents tab to identify the specific states and confirm TPP eligibility by state.
- **Plan of Allocation Not Summarized:** Per-claimant payment estimates are unavailable from the home page. The Plan of Allocation is referenced as available in the Court Documents tab; FRS staff should review it to advise clients on expected recovery.
- **Excluded Parties List Incomplete:** Only "for resale" purchasers are explicitly excluded on the home page. The full exclusions list requires review of the Class Notice/Settlement Agreement.
- **No Internal Contradictions Detected:** The filing deadline (July 31, 2026) is in the future relative to the Last Updated date (2026-09-22) — **FLAG: The filing deadline of July 31, 2026 has already passed as of the Last Updated date of September 22, 2026.** This is a significant contradiction — the article states the claim deadline is July 31, 2026, but the knowledge base article is being published on September 22, 2026, meaning the deadline has already elapsed. FRS staff should verify current case status, whether the deadline was extended, and whether the Fairness Hearing occurred as scheduled on August 5, 2026. The settlement website should be checked immediately for updated announcements.
- **Fairness Hearing Status:** The Fairness Hearing was scheduled for August 5, 2026 — also in the past as of the Last Updated date. Settlement approval status should be confirmed and this article updated accordingly.